AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Zymeworks to Present at Jefferies 2019 Global Healthcare Conference

May 28, 2019

VANCOUVER, British Columbia--(BUSINESS WIRE)--May 28, 2019--

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Jefferies 2019 Global Healthcare Conference taking place June 4-7, 2019 in New York, NY.

The Company’s presentation will be Friday, June 7, 2019 at 12:30 p.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at  http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. The Company’s suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. The Company’s second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit  www.zymeworks.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005141/en/

CONTACT: Zymeworks Inc.

Investor Inquiries:

Ryan Dercho, Ph.D.

(604) 678-1388

ir@zymeworks.comTiffany Tolmie

(604) 678-1388

ir@zymeworks.comMedia Inquiries:

Angela Bitting

(925) 202-6211

a.bitting@comcast.net

KEYWORD: UNITED STATES NORTH AMERICA CANADA NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Zymeworks Inc.

Copyright Business Wire 2019.

PUB: 05/28/2019 06:45 AM/DISC: 05/28/2019 06:45 AM

http://www.businesswire.com/news/home/20190528005141/en

All contents © copyright 2019 The Associated Press.All rights reserved.